DF
NVAX icon

Donoghue Forlines’s Novavax NVAX Stock Holding History

Donoghue Forlines’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-6,700
Closed -$493K – 279
2022
Q1 		$493K Buy
6,700
+3,321
+98% +$296K 0.11% 251
2021
Q4 		$483K Sell
3,379
-192
-5% -$33K 0.08% 236
2021
Q3 		$740K Buy
3,571
+25
+0.7% +$5.51K 0.14% 155
2021
Q2 		$753K Buy
3,546
+448
+14% +$82.1K 0.14% 156
2021
Q1 		$562K Sell
3,098
-327
-10% -$65.2K 0.11% 178
2020
Q4 		$382K Buy
+3,425
New +$364K 0.07% 214

Other funds holding NVAX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Voloridge Investment Management
Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Donoghue Forlines's NVAX Position: Q2 2022 in Review

Donoghue Forlines sold out of Novavax (NVAX) in Q2 2022, closing a stake of 6,700 shares — an estimated $493K sold.

Donoghue Forlines first reported a position in NVAX in Q4 2020 and held it in 6 quarters. The position peaked at $753K in Q2 2021. 325 funds tracked by Wall St. Rank hold NVAX as of Q2 2022.

  • Donoghue Forlines reported no remaining Novavax position as of Q2 2022 after selling out during the quarter.
  • Donoghue Forlines sold 6,700 Novavax shares in Q2 2022, an estimated $493K.
  • Donoghue Forlines first reported a position in Novavax in Q4 2020 and held it in 6 quarters.
  • Donoghue Forlines's Novavax position peaked at $753K in Q2 2021.
  • 325 funds tracked by Wall St. Rank held Novavax as of Q2 2022.

Based on Donoghue Forlines's 13F filing for Q2 2022, filed 8 Aug 2022.